glp-1 news today 2025 november 5 Weight-Loss Drug Demonstration Begins July 2026 2026 is the year of

In 2020 another open-label RCT of triple therapy with or without NAC, 1200 mg per day, was published, and reported that addition of NAC did not improve eradication rates

In July of 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion, and one year later AstraZeneca purchased the Bristol-Myers Squibb share of the diabetes joint venture

They help reduce inflammation, speed up healing, and prevent further damage to the skin

FDA-approved semaglutide (sold as Ozempic for diabetes and Wegovy for weight management) goes through rigorous clinical trials, manufacturing validation, and ongoing post-market surveillance